This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oct. 1, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, or the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today announced the successful completion of the manufacturing environmental assessment at its 250-ton Jiangchuan Macrolide Facility (JCM).
The environmental assessment (EA) examines various aspects of the plant operation, macrolide API production along with relevant indices that are required to be in compliance with the environmental regulatory guidelines established by the PRC government. These aspects include: 1) Surface and ground water environmental quality status, 2) Ambient air quality status, 3) API production industrial ingredients recycling, disposal and management, 4) Exhaust emissions, 5) Waste water pre-treatment recycling and management, 6) Noise environmental impact and assessment.
Following the on-site examination at the end of September, the environmental assessment and protection authorities concluded that JCM project has met the national industrial policy and environmental protection guidelines for clean production process using state-of-the-art technologies. The authorities also concluded that the facility has achieved the satisfactory implementation of the Environmental Impact Assessment (EIA) regulations based on the proposed environmental measures. JCM facility is now approved for initiation of GMP certification process.
About TPIHeadquartered at
Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of
China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.
For more information about TPI, please visit:
Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.